litlas
Log inCreate account

C. David Sjöström

Active 1995–2024

64
Papers
19,855
Citations
45
h-index
64
i10-index

Citations

Citations per year for C. David Sjöström1996: 1 citations1997: 3 citations1998: 5 citations1999: 8 citations2000: 14 citations2001: 20 citations2002: 25 citations2003: 32 citations2004: 38 citations2005: 44 citations2006: 18 citations2007: 32 citations2008: 94 citations2009: 118 citations2010: 94 citations2011: 96 citations2012: 114 citations2013: 146 citations2014: 153 citations2015: 143 citations2016: 139 citations2017: 136 citations2018: 130 citations2019: 379 citations2020: 490 citations2021: 795 citations2022: 851 citations2023: 833 citations2024: 1,133 citations2025: 556 citations2026: 18 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,084 citing papers, 21.2% of this breakdownUnited Kingdom: 850 citing papers, 8.6% of this breakdownChina: 543 citing papers, 5.5% of this breakdownItaly: 481 citing papers, 4.9% of this breakdownGermany: 453 citing papers, 4.6% of this breakdownCanada: 416 citing papers, 4.2% of this breakdownAustralia: 403 citing papers, 4.1% of this breakdownSweden: 379 citing papers, 3.9% of this breakdownNetherlands: 366 citing papers, 3.7% of this breakdownJapan: 330 citing papers, 3.4% of this breakdownFrance: 294 citing papers, 3% of this breakdownSpain: 287 citing papers, 2.9% of this breakdown
0%21.2%Other 30%

Institutions

Fields

  • Medicine90.2%
  • Biochemistry, Genetics and Molecular Biology4.7%
  • Physics and Astronomy1.6%
  • Neuroscience0.8%
  • Health Professions0.8%
  • Nursing0.4%
  • Other1.5%

Topics

  • Diabetes Treatment and Management14.2%
  • Bariatric Surgery and Outcomes8.7%
  • Chronic Kidney Disease and Diabetes5.9%
  • Pancreatic function and diabetes4.4%
  • Diet and metabolism studies3.8%
  • Metabolism, Diabetes, and Cancer3.3%
  • Other59.7%

Coauthors

All papers

Open in search
  1. Dapagliflozin in Patients with Chronic Kidney Disease

    Authors: Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Johannes F.E. Mann, John J.V. McMurray, Magnus Lindberg, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna-Maria Langkilde, David C. Wheeler - New England Journal of Medicine 2020 cited by 5,197

  2. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

    Authors: Lars Sjöström, Kristina Narbro, C. David Sjöström, Kristjan Karason, Bo Larsson, Hans Wedel, Ted Lystig, Marianne Sullivan, Claude Bouchard, Björn Carlsson, Calle Bengtsson, S Dahlgren, Anders Gummesson, Peter Jacobson, Jan Karlsson, Anna‐Karin Lindroos, Hans Lönroth, Ingmar Näslund, Torsten Olbers, Kaj Stenlöf, Jarl Torgerson, Göran I. Ågren, Lena Carlsson - New England Journal of Medicine 2007 cited by 4,629

  3. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

    Authors: David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink - The Lancet Diabetes & Endocrinology 2020 cited by 530

  4. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

    Authors: David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits‐Filho, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink - Kidney International 2021 cited by 397

  5. Bariatric Surgery and Long-term Cardiovascular Events

    Authors: Lars Sjöström, Markku Peltonen, Peter Jacobson, C. David Sjöström, Kristjan Karason, Hans Wedel, Sofie Ahlin, Åsa Anveden, Calle Bengtsson, Gerd Bergmark, Claude Bouchard, Björn Carlsson, S Dahlgren, Jan Karlsson, Anna‐Karin Lindroos, Hans Lönroth, Kristina Narbro, Ingmar Näslund, Torsten Olbers, Per‐Arne Svensson, Lena Carlsson - JAMA 2012 cited by 1,623

  6. Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region

    Authors: Patrik Sibolt, Lina Andersson, L. Calmels, C. David Sjöström, Ulf Bjelkengren, Poul Geertsen, C.F. Behrens - Physics and Imaging in Radiation Oncology 2020 cited by 248

  7. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    Authors: Niels Jongs, Tom Greene, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink - The Lancet Diabetes & Endocrinology 2021 cited by 208

  8. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    Authors: Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, Jose Luis Gorriz, Fan Fan Hou, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink - Journal of the American Society of Nephrology 2021 cited by 196

  9. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    Authors: Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Tom Greene - The Lancet Diabetes & Endocrinology 2021 cited by 194

  10. Once-Weekly Exenatide in Youth With Type 2 Diabetes

    Authors: William V. Tamborlane, Raafat Bishai, David H. Geller, Naim Shehadeh, Dalia Al‐Abdulrazzaq, Evelina Mánica Vazquez, Eva Karoly, Tünde Troja, Orlando Doehring, Debra Carter, John T. Monyak, C. David Sjöström - Diabetes Care 2022 cited by 89

  11. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Authors: David C. Wheeler, Bergur V. Stefánsson, М. М. Батюшин, Oleksandr Bilchenko, David Z.I. Cherney, Glenn M. Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits‐Filho, Hans Furuland, José Luis Górriz, Tom Greene, Hermann Haller, Fan Fan Hou, Shin‐Wook Kang, Rey Isidto, Dinesh Khullar, Patrick B. Mark, John J.V. McMurray, Naoki Kashihara, Michał Nowicki, Frederik Persson, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, Kausik Umanath, Pham Van Bui, István Wittmann, Magnus Lindberg, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink - Nephrology Dialysis Transplantation 2020 cited by 190

  12. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

    Authors: Niels Jongs, Glenn M. Chertow, Tom Greene, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Naoki Kashihara, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink - Journal of the American Society of Nephrology 2022 cited by 86

  13. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial

    Authors: Lars Sjöström, Anders Gummesson, C. David Sjöström, Kristina Narbro, Markku Peltonen, Hans Wedel, Calle Bengtsson, Claude Bouchard, Björn Carlsson, S Dahlgren, Peter Jacobson, Kristjan Karason, Jan Karlsson, Bo Larsson, Anna‐Karin Lindroos, Hans Lönroth, Ingmar Näslund, Torsten Olbers, Kaj Stenlöf, Jarl Torgerson, Lena Carlsson - The Lancet Oncology 2009 cited by 759

  14. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    Authors: Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, José Luis Górriz, Fan Fan Hou, McMurray, JJV, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, Heerspink, HJL, DAPA-CKD Trial Committees and Investigators, . - 2021 cited by 101

  15. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

    Authors: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J.L. Heerspink, Stephanie M. Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman - Cardiovascular Diabetology 2019 cited by 94

  16. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

    Authors: Serge Jabbour, Juan P. Frías, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C. David Sjöström, Cristian Guja - Diabetes Care 2020 cited by 68

  17. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

    Authors: Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner, Peter Rossing, C. David Sjöström, David C. Wheeler, Anna Maria Langkilde, Hiddo J.L. Heerspink - The Lancet Diabetes & Endocrinology 2019 cited by 200

  18. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

    Authors: John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Claes Held, Fan Fan Hou, Johannes F.E. Mann, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna Maria Langkilde, Hiddo J.L. Heerspink - Circulation 2020 cited by 141

  19. Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study

    Authors: Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs, Dennis B. Rouw, C. David Sjöström, Iris Friedli, L. E. B. Johansson, Daniël H. van Raalte, Klaas Hoogenberg, Hiddo J.L. Heerspink - Diabetes Obesity and Metabolism 2023 cited by 29

  20. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

    Authors: Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs, Glenn M. Chertow, Mikhail Kosiborod, Fan Fan Hou, John J.V. McMurray, Peter Rossing, Ricardo Correa‐Rotter, Raisa Kurlyandskaya, Bergur V. Stefánsson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Ricardo Correa‐Rotter, Tom Greene, Fan Fan Hou, John J.V. McMurray, Peter Rossing, Robert D. Toto, Bergur V. Stefánsson, Anna Maria Langkilde, Laura Maffei, Pablo Raffaele, S. Solís, César A. Arias, Dov Aizenberg, Carolina Lúquez, Cesar Javier Zaidman, Natalia Cluigt, M. Mayer, A Alvarisqueta, A. Wassermann, Rafaël Maldonado, J. Bittar, M. Maurich, L.E. Gaite, Nicole Garcia, Leonardo Sivak, Pablo Ramallo, Juan Carlos Santos, Ruben Garcia Duran, Juan Oddino, A Marañón, Lília Nigro Maia, Dánae Duana Ávila, Elvino Barros, Maria H Vidotti, Daniel Panarotto, Irene de Lourdes Noronha, Luiz Alberto Andreotti Turatti, Luciane Mônica Deboni, María Eugênia Fernandes Canziani, Miguel C. Riella, Marcelo Rodrigues Bacci, Raphael Paschoalin, R. J. Franco, João Carlos Goldani, Eric St-Amour, Ann Steele, Ronald Goldenberg, S.B. Pandeya, Harpreet S. Bajaj, David Z.I. Cherney, Stéphanie Kaiser, James Conway, Sharron Chow, G.S. Bailey, Jean‐Philippe Lafrance, Jonathan Winterstein, Serge Cournoyer, Daniel Gaudet, F. Madore, Robyn L. Houlden, Ashley Dowell, Michel R. Langlois, Nicola Muirhead, Hasnain Khandwala, Anna S. Levin, Fan Fan Hou, Ying Xue, Zuo Li, Chuan‐Ming Hao, Zhaohui Ni, C Xing, N Chen, Yugang Dong, Rong Zhou, Xiao Xu, Yiping Zou, Chu Wang, Liu B, Qian Chen, Miao Lin, Qin Luo, David Zhang, Jing Wang and 339 more - European Heart Journal 2021 cited by 122

  21. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial

    Authors: David C. Wheeler, Niels Jongs, Bergur V. Stefánsson, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Anna Maria Langkilde, John J.V. McMurray, Peter Rossing, Michał Nowicki, István Wittmann, Ricardo Correa‐Rotter, C. David Sjöström, Robert D. Toto, Hiddo J.L. Heerspink - Nephrology Dialysis Transplantation 2021 cited by 94

  22. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

    Authors: Paola Fioretto, Stefano Del Prato, John B. Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström, Peter Sartipy, On Behalf of the DERIVE Study Investigators - Diabetes Obesity and Metabolism 2018 cited by 191

  23. Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits

    Authors: Lina M. Åström, C.F. Behrens, L. Calmels, C. David Sjöström, Poul Geertsen, Lene Sonne Mouritsen, Eva Serup‐Hansen, Henriette Lindberg, Patrik Sibolt - Radiotherapy and Oncology 2022 cited by 111

  24. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Authors: John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa‐Rotter, Glenn M. Chertow, Fan Fan Hou, Peter Rossing, C. David Sjöström, Scott D. Solomon, Robert D. Toto, Anna Maria Langkilde, Hiddo J.L. Heerspink - JACC Heart Failure 2021 cited by 106